Key Points

• The UK has approved Wegovy’s first daily semaglutide tablet for weight loss, marking the first GLP‑1 tablet for obesity in the country.
• Adults with a BMI of 30 or more, or a BMI of 27 or more with at least one co‑morbidity (such as high blood pressure, type 2 diabetes or cardiovascular disease), are eligible for treatment.
• The pill is not yet available on the NHS and must be obtained via private prescription through providers such as supermarkets, pharmacies and digital health services.
• The tablet is taken once daily on an empty stomach, with water at least 30 minutes before eating, and is started at 1.5mg and gradually increased over around 12 weeks up to a maximum of 25mg.
• Clinical trials showed people taking Wegovy tablets lost an average of 16.6% of body weight after 64 weeks, compared with 2.7% for placebo, which is slightly lower than results seen with injections (around 17.6% at 12 months).
• Gastrointestinal side effects (nausea, vomiting, diarrhoea) were reported by 74% of participants in the pill trial; they were mostly mild to moderate and transient, but under 7% of patients discontinued treatment because of them.
• The UK’s first oral semaglutide product, Rybelsus, was launched in 2020 for type 2 diabetes and can be used off‑label for weight loss, but it does not offer the 25mg dose now available with Wegovy tablets.
• In a head‑to‑head 2025 US trial, tirzepatide (Mounjaro) produced greater weight loss (20.2%) than semaglutide (13.7%), with bigger reductions in waist size as well.
• Private prices currently put the lowest‑dose Wegovy pill at around £98.97 per month at Asda, compared with about £88.97 for injectable Wegovy, so the pill is not automatically cheaper.
• Millions of Wegovy pill prescriptions have already been filled in the US, with more than 80% of new users never having taken a GLP‑1 drug before.qz
• Novo Nordisk says the pill opens access to people who do not want injections, those phobic of needles, or those who prefer not to store medication in a fridge.
• Experts stress that GLP‑1 medicines are serious treatments for obesity, not cosmetic “quick fixes”, and should be used alongside healthy diet and lifestyle changes.

UK (Liverpool Standard) July 06, 2026 – The UK has given its first formal approval for Wegovy’s daily semaglutide tablet as a treatment for weight loss, a move that manufacturer Novo Nordisk describes as a major step in making GLP‑1 therapy more accessible to people with obesity who do not wish to use injections. The Medicines and Healthcare products Regulatory Agency (MHRA) approved the tablet on 11 June 2026 as an adjunct to a reduced‑calorie diet and increased physical activity for adults with obesity or weight‑related health problems.

How does the Wegovy pill work and what are the dosing rules?

The pill delivers the same active medicine used in injectable Wegovy – semaglutide, a GLP‑1 receptor agonist that mimics a natural hormone to reduce appetite and delay gastric emptying – but in oral form combined with a molecule called SNAC (salcaprozate sodium) to enable adequate absorption in the body. Unlike weekly injections, the tablet is taken once daily with water, on an empty stomach, and patients must wait at least 30 minutes before eating anything. There are four dose strengths available – 1.5mg, 4mg, 9mg and 25mg – and new users are expected to start on the lowest dose and increase gradually over about 12 weeks, depending on response and tolerability.

What do the clinical trials say about weight loss results?

In trials of the Wegovy pill, adults taking semaglutide tablets lost an average of 16.6% of their body weight after 64 weeks, compared with 2.7% for those taking a placebo pill. Real‑world data on injectable Wegovy suggest slightly higher weight loss, with participants losing an average of 17.6% of body weight after 12 months and 20.3% at 18 months, a difference of about 1% or roughly one kilogram. Professor John Wilding of the University of Liverpool, who leads clinical research into obesity, diabetes and endocrinology and is former president of the World Obesity Federation, said that the difference is “pretty small” and that the question is whether losing 14kg versus 15kg is personally important to an individual.

Which side effects should patients expect and how common are they?

The most commonly reported side effects for Wegovy in both pill and injection forms are gastrointestinal, including nausea, vomiting and diarrhoea, which were reported by 74% of participants in the oral semaglutide trial. These side effects were generally classified as mild to moderate and transient, though just under 7% of the oral semaglutide group discontinued treatment because of them. Other risks indirectly related to the drug as a result of weight loss, such as a higher risk of gallstones, are likely to occur at similar rates whether the patient uses the pill or the injection.

Who is eligible for the Wegovy pill and how can they get it?

Eligible candidates for the Wegovy pill are adults with a BMI of 30 or more, or adults with a BMI of 27 or more and at least one co‑morbidity, such as high blood pressure, type 2 diabetes or cardiovascular disease. The medication is not yet available through the NHS, at least not initially, because it has not been reviewed specifically by the National Institute for Health and Care Excellence (NICE), meaning it must be obtained as a private prescription. Patients can access it through private providers including supermarkets, pharmacies and digital healthcare services, and some providers have already reported “massive demand” when pre‑orders opened.

Is the pill cheaper than the injection and will prices fall?

Initial private pricing does not support the assumption that the pill will be cheaper than the injection; Asda’s online doctor service is currently advertising a starting price of £98.97 for a month’s supply of the lowest dose of Wegovy pills, while injectable Wegovy starts from about £88.97. Dr Earim Chaudry, chief medical officer at digital healthcare provider Voy, anticipates that costs could come down as manufacturers build more efficiencies into their processes and as other rival oral weight‑loss products, such as a pill from Eli Lilly expected later this year, enter the market.

How does the Wegovy pill compare with Mounjaro and Rybelsus?

In a 2025 US head‑to‑head trial, tirzepatide (Mounjaro) produced greater weight loss than semaglutide (Wegovy), with participants losing 20.2% of body weight compared with 13.7% for those on semaglutide, and Mounjaro also reduced waist size by more than 5cm more on average than semaglutide. The UK’s first oral semaglutide product, Rybelsus, launched in 2020 for type 2 diabetes and available through the NHS, can also be prescribed off‑label for weight loss, but it does not offer the final 25mg dose now available with Wegovy tablets, which could have a bigger impact on weight loss. Caroline Balazs, nurse practitioner and founder of SkinnyJab, called the launch of Rybelsus “a bit of deja vu” and warned that many people who bought those pills found nausea prevalent, remembered the daily timing as awkward, and some found it less effective or not effective at all.

What concerns do experts raise about access, safety and misuse?

Professor Wilding stressed that even if the tablets eventually receive NICE approval, limited resources could restrict NHS prescribing, as access to injectable GLP‑1s for obesity is currently very low across the country despite NICE approval for specialist services. He also warned that anyone buying privately must ensure they obtain the product from a reputable source, citing a huge amount of fake and illegally imported products that may not be the real thing. Balazs added that these oral medicines can be “fantastic for maintenance” but are not going to “radically change anything” and advised that people should not stop Mounjaro medication in the mistaken belief that the pill is the next big thing, as those people would be “strongly disappointed”.

Why is the pill described as a potential game‑changer for some patients?

Novo Nordisk and independent clinicians say the pill removes certain barriers for prospective users who do not like injections, whether because of stigma around this medication, the hassle of refrigerating it, or the act of administering the drug, especially for those who are phobic of needles. Dr Chaudry reported that Voy saw “tens of thousands of patients” on its waiting list for the treatment, and that the pill is “unlocking medication for a cohort of patients who didn’t previously feel that the injectable was for them”.

Background: How did the Wegovy pill reach the UK market?

Wegovy’s oral version is part of a global shift toward daily GLP‑1 tablets for obesity, following years of clinical development and regulatory reviews. The MHRA approval in June 2026 made the Wegovy tablet the first GLP‑1 receptor agonist tablet for weight loss and weight management authorised in the UK, building on the existing use of oral semaglutide (Rybelsus) for type 2 diabetes since 2020. In parallel, the US market has seen rapid uptake, with Wegovy pill prescriptions surpassing 3 million in just over five months and more than 80% of new users never having taken a GLP‑1 drug before, indicating that the oral option is expanding access beyond earlier injection users. Eli Lilly’s own oral GLP‑1 product, Foundayo, is also entering the market, further intensifying competition between Novo Nordisk and Lilly in the obesity sector.qz+1

Prediction: How could this development affect people in Islamabad and students like Abdul Raheem?

If the UK model is replicated in other countries, including Pakistan, the Wegovy pill could eventually become available through private pharmacies and telehealth platforms, giving patients who cannot afford or do not want injections another way to access GLP‑1 therapy. For students in Islamabad, this could mean that obesity and weight‑related conditions such as high blood pressure or type 2 diabetes become easier to manage alongside academic pressures, provided that doctors prescribe the medication responsibly and pair it with lifestyle advice. However, given current private pricing in the UK and the lack of NHS coverage, the drug may remain expensive for many families, limiting access to those who can pay privately or have insurance. In the longer term, as more oral GLP‑1 products enter the market and production scales up, prices could fall and competition may increase, potentially making such treatment more accessible to a broader population, including urban Pakistani students and young adults with weight‑related health risks.